Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02012140
Recruitment Status : Unknown
Verified December 2013 by Paul A. Gurbel, LifeBridge Health.
Recruitment status was:  Not yet recruiting
First Posted : December 16, 2013
Last Update Posted : December 16, 2013
Information provided by (Responsible Party):
Paul A. Gurbel, LifeBridge Health

Brief Summary:
Ticagrelor therapy has been shown to reduce the rates of cardiovascular events and all-cause mortality compared to clopidogrel therapy in patients with acute coronary syndromes (ACS). The benefit of this study would be to demonstrate that ticagrelor therapy is associated with equivalent platelet inhibition irrespective of the disease status in patients undergoing PCI.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Stable Angina Myocardial Infarction Coronary Artery Disease Drug: ticagrelor Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2014
Estimated Primary Completion Date : January 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Ticagrelor

Arm Intervention/treatment
Experimental: Ticagrelor
As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
Drug: ticagrelor

Primary Outcome Measures :
  1. Inhibition of platelet aggregation [ Time Frame: Pre-LD dose, 0.5, 1, 2, 3, 4-6, the next day just before and 1, 2 and 4 hours after morning maintenance dose and pre-dose and 1, 2 and 4 hours after the last study MD dose (14 +/- 3 days). ]
    The primary end point is the pharmacodynamic (inhibition of platelet aggregation, IPA) effect of 180mg LD ticagrelor measured at 1hour post-dose by 20uM ADP-induced maximum platelet aggregation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable Angina: Stable coronary artery disease patients with documented ischemia undergoing elective PCI will be enrolled.Inclusion criteria for enrollment in the ACS group with or without ST-segment elevation, requires onset of symptoms during the previous 48 hours.


For patients who had an ACS without ST-segment elevation (NTSEMI), two of the following criteria had to be met:

  • a positive test of a biomarker (troponin I) in accordance with the universal definitions indicating myocardial necrosis
  • ST-segment changes on electrocardiography, indicating ischemia that do not meet criteria for STEMI.


For patients who had an ACS with ST-segment elevation, the following two inclusion criteria had to be met:

  • either persistent ST-segment elevation of at least 0.1 mV in at least two contiguous leads or a new left bundle-branch block; and
  • the intention to perform primary PCI with 24 hours of symptom onset

Exclusion Criteria:

  • Patients who are on P2Y12 receptor blockers, oral anticoagulants, or GPIIb/IIIa receptor blocker therapies.
  • Presence or history of any of the following: ischemic or hemorrhagic stroke; transient ischemic attack (TIA); intracranial neoplasm; arteriovenous malformation, or aneurysm; intracranial hemorrhage; head trauma (within 3 months of study entry)
  • History of refractory ventricular arrhythmias or an increased risk of bradycardic events (eg, subjects without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree atrioventricular (AV) block or bradycardic-related syncope)
  • History or evidence of congestive heart failure (New York Heart Association Class III or above ≤ 6 months before screening
  • Severe hepatic impairment defined as ALT> 2.5 X ULN
  • Uncontrolled hypertension, or systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg at screening
  • Severely impaired renal function (glomerular filtration rate < 30 mL/minute) or on dialysis
  • Platelet count <100 X103, illicit drug or alcohol abuse, prothrombin time>1.5 times control, haematocrit <30%, and creatinine >2.0 mg/dl.
  • Contraindication or other reason that ticagrelor should not be administered (eg, hypersensitivity, active bleeding, moderate or severe liver disease, history of previous intracranial bleed, GI bleed within the past 6 months, major surgery within 30 days)
  • Fibrinolytic therapy in the 24 hours prior to PCI, or planned fibrinolytic treatment following PCI.
  • Participation in another investigational drug or device study in the last 30 -Pregnancy or lactation
  • Concomitant oral or intravenous therapy (see examples below) with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers which cannot be stopped for the course of the study
  • Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir
  • Substrates with narrow therapeutic index: cyclosporine, quinidine
  • Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine
  • Any other condition which in the opinion of the investigator, may either put the patient at risk or influence the result of the study (eg, cardiogenic shock or severe haemodynamic instability, active cancer, risk for non-compliance, risk for being lost to follow up)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02012140

Layout table for location information
United States, Maryland
Sinai Center for Thrombosis Research
Baltimore, Maryland, United States, 21215
Contact: Kevin Bliden, MBA    410-601-4795   
Sponsors and Collaborators
LifeBridge Health
Layout table for investigator information
Principal Investigator: Paul Gurbel, MD Sinai Center for Thrombosis Research

Layout table for additonal information
Responsible Party: Paul A. Gurbel, Director, LifeBridge Health Identifier: NCT02012140    
Other Study ID Numbers: AZSC01
First Posted: December 16, 2013    Key Record Dates
Last Update Posted: December 16, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Infarction
Angina, Stable
Cardiovascular Diseases
Pathologic Processes
Coronary Disease
Myocardial Ischemia
Heart Diseases
Arterial Occlusive Diseases
Vascular Diseases
Angina Pectoris
Chest Pain
Neurologic Manifestations
Signs and Symptoms
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs